Pfizer has selected the University at Buffalo’s Jacobs School of Medicine to be part of an international study of its antiviral drug Paxlovid, and its potential to treat juvenile COVID patients. The oral treatment, which the FDA approved for emergency treatment of adult patients in December 2021, was found to reduce hospitalizations and even fatalities among symptomatic adult COVID patients.